Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Debora Santoro"'
Autor:
Dave Singh, Aida Emirova, Catherine Francisco, Debora Santoro, Mirco Govoni, Marie Anna Nandeuil
Publikováno v:
Respiratory Research, Vol 21, Iss 1, Pp 1-11 (2020)
Abstract Background This study evaluated the efficacy, safety and tolerability of the novel inhaled phosphodiesterase-4 inhibitor CHF6001 added-on to formoterol in patients with chronic obstructive pulmonary disease (COPD). Methods Randomised, double
Externí odkaz:
https://doaj.org/article/54324e839ad648d38f678378c9d738ed
Autor:
Lizhong Du, Xiaomei Tong, Chao Chen, Xirong Gao, Alessandra Gagnatelli, Jingyang Li, Debora Santoro, Sara Nicolardi, Laura Fabbri, The Peyona Chinese Study Group
Publikováno v:
Frontiers in Pediatrics, Vol 8 (2020)
Background: Caffeine citrate has been approved in China for the management of apnea of prematurity. This clinical trial was conducted as a condition of regulatory approval. The aim was to confirm the efficacy of caffeine citrate in the treatment of r
Externí odkaz:
https://doaj.org/article/eaabe1c430cb4322bb3c21e6d5f31858
Publikováno v:
American Journal of Respiratory and Critical Care Medicine.
Autor:
Christian P. Speer, Debora Santoro, Dorothea Del Buono, Zbynek Straňák, Dominique Singer, Richard Plavka, Paul Clarke, David G. Sweet, Laura Fabbri, Guido Varoli, Mark A. Turner, Rangmar Goelz, Ben Stenson, Annalisa Piccinno
Objective: To assess at 24 months corrected age (CA) the neurological, respiratory, and general health status of children born prematurely from 27 +0 to 33 +6 weeks’ gestation who were treated in a first-in-human study with a new fully synthetic su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fde1c7228ef54599d3be8e0040afa614
https://ueaeprints.uea.ac.uk/id/eprint/78032/
https://ueaeprints.uea.ac.uk/id/eprint/78032/
Autor:
Carlo Dani, Gyula Talosi, Annalisa Piccinno, Virginia Maria Ginocchio, Gyorgy Balla, Anna Lavizzari, Zbynek Stranak, Eloisa Gitto, Stefano Martinelli, Richard Plavka, Barbara Krolak-Olejnik, Gianluca Lista, Francesca Spedicato, Giorgia Ciurlia, Debora Santoro, David Sweet
Publikováno v:
The Journal of pediatrics. 246
To investigate the efficacy and safety of nebulized poractant alfa (at 200 and 400 mg/kg doses) delivered in combination with nasal continuous positive airway pressure compared with nasal continuous positive airway pressure alone in premature infants
Publikováno v:
Clinical problems.
Autor:
Rangasamy Ramanathan, Manoj Biniwale, Krishnamurthy Sekar, Nazeeh Hanna, Sergio Golombek, Jatinder Bhatia, Martha Naylor, Laura Fabbri, Guido Varoli, Debora Santoro, Dorothea Del Buono, Annalisa Piccinno, Christiane E. Dammann
Publikováno v:
The Journal of pediatrics. 227
COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition
Autor:
Oliver Kornmann, Brendan Colgan, Aida Emirova, Brian Leaker, Debora Santoro, Dave Singh, Marie Anna Nandeuil, Deborah Balzano, Henrik Watz, Germano Lucci, Mirco Govoni, Kai Michael Beeh
Publikováno v:
The European Respiratory Journal
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Patients with COPD who have higher eosinophil numbers in the airways and peripheral blood demonstrate a greater clinical response to inhaled corticosteroids (ICS) [1–3]. Furthermore, the effect of the oral phosphodiesterase-4 (PDE4) inhibitor roflu
Autor:
Debora Santoro, Nazeeh Hanna, Sergio Golombek, Annalisa Piccinno, Jatinder Bhatia, Rangasamy Ramanathan, Dorothea Del Buono, K C Sekar, Christiane E.L. Dammann, Guido Varoli, Laura Fabbri, Manoj Biniwale, Martha E. Naylor
Publikováno v:
The Journal of pediatrics. 225
Objective To compare efficacy and safety of a new synthetic surfactant, CHF5633, enriched with surfactant proteins, SP-B and SP-C peptide analogues, with porcine surfactant, poractant alfa, for the treatment of respiratory distress syndrome in infant
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Fabrizia Mariotti,1 Mirco Govoni,1 Germano Lucci,1 Debora Santoro,1 Marie Anna Nandeuil2 1Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy; 2Global Clinical Development, Chiesi S.A.S., Courbevoie, France Purpose: The purpose of this